A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (NSC# 606869) in the Very High Risk Stratum

Trial Profile

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (NSC# 606869) in the Very High Risk Stratum

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Antineoplastics; Clofarabine; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Etoposide; Folinic acid; Hydrocortisone sodium succinate; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Tioguanine; Vincristine
  • Indications Acute lymphoblastic leukaemia; Down syndrome; Osteonecrosis; Pain
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 This trial has been suspended in Ireland as per European Clinical Trials Database record.
    • 08 Dec 2015 Pooled results of 2 trials including this study and another study [see CTP 700003195] were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 21 Nov 2013 Planned number of patients changed from 5000 to 4895 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top